FIELD: medicine, pharmacology. SUBSTANCE: the innovation is described to use a liquid cartilaginous extract containing the molecules of up to 500 kDa molecular weight as a preparation to protect a patient against toxic side effects as a result of antineoplastic agents injected. Cartilaginous extract could be used in the content of either pharmaceutical composition or therapeutic kit containing an antineoplastic agent. EFFECT: combined therapy provides higher efficiency of antitumor action due to decreased number of toxic side effects. 6 cl, 3 dwg, 4 tbl
Authors
Dates
2003-01-10—Published
1998-03-11—Filed